Physician Views snap poll: AbbVie builds out clinical case for Rinvoq in psoriatic arthritis; how do rheumatologists perceive the data?

The catalyst: Earlier this month, AbbVie released positive top-line data from a second Phase III study evaluating its JAK inhibitor Rinvoq as a treatment for psoriatic arthritis. These latest data demonstrate Rinvoq’s efficacy in patients previously untreated with a biologic therapy; positive Phase III data released last year evaluated use in patients who had an inadequate response to an anti-TNF inhibitor.

The poll: We are asking rheumatologists (based in the US, France, Germany and UK) to assess both data sets and evaluate how these results may impact their future utilisation of Rinvoq for the treatment of psoriatic arthritis.

___________

Q. New Phase III data (SELECT-PsA1) has been released showing that two doses of the oral, once-daily JAK inhibitor Rinvoq (upadacitinib; 15mg and 30mg) met the primary endpoint of ACR20 response at week 12 versus placebo in adult patients with active psoriatic arthritis who have responded inadequately or are intolerant to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs). Results show that at week 12, 71% and 79% of patients receiving 15 mg and 30 mg of Rinvoq achieved ACR20, respectively, compared to 36% of patients receiving placebo. 

How compelling are these efficacy data for the treatment of active psoriatic arthritis patients who have responded inadequately or are intolerant to one or more non-biologic DMARDs?

1 – Not compelling

2

3

4

5 – Very compelling

___________

Q. Last year, Phase III data (SELECT-PsA2) was released showing that two doses of Rinvoq (upadacitinib; 15mg and 30mg) met the primary endpoint of ACR20 response at week 12 versus placebo in adult patients with active psoriatic arthritis who have responded inadequately to one or more biologic disease modifying anti-rheumatic drugs (bDMARDs). Results show that at week 12, 57% and 64% of patients receiving 15 mg and 30 mg of Rinvoq achieved ACR20, respectively, compared to 24% of patients receiving placebo.

How compelling are these efficacy data for the treatment of active psoriatic arthritis patients who have responded inadequately to one or more biologic disease modifying anti-rheumatic drugs (bDMARDs)?

1 – Not compelling

2

3

4

5 – Very compelling

___________

Q. In the SELECT-PsA1 study, through week 24, serious infections occurred in 1.2% and 2.6% of patients in the 15 mg and 30 mg Rinvoq (upadacitinib) groups, respectively, compared to 0.9% in the placebo group. There was one case of adjudicated venous thromboembolic events (VTE) in the Rinvoq 30 mg group (0.2%), no cases in the Rinvoq 15 mg group and one case in the placebo group (0.2%). No major adverse cardiovascular events (MACE) were reported in the Rinvoq groups and one reported in the placebo group.

In the SELECT-PsA2 study, through week 24 serious infections occurred in 0.5/2.8% of patients in the 15/30 mg Rinvoq groups, respectively, compared to 0.5 percent in the placebo group. There was one pulmonary embolism reported in the 15 mg Rinvoq group and none in the 30 mg and placebo groups. There was one non-fatal adjudicated major adverse cardiovascular event (MACE) in the 15 mg Rinvoq group (acute myocardial infarction) and no MACE in the 30 mg and placebo groups.

How compelling is Rinvoq’s safety profile?

1 – Not compelling

2

3

4

5 – Very compelling

___________

Q. Taking the totality of these efficacy and safety data into account, how would you assess your likely future use of Rinvoq (upadacitinib) as an alternative treatment to currently available therapies in psoriatic arthritis patients who have yet to receive treatment with a biologic therapy?

Much less likely to use

Less likely to use

Use comparably

More likely to use

Much more likely to use

___________

Q. Taking the totality of these efficacy and safety data into account, how would you assess your likely future use of Rinvoq (upadacitinib) as an alternative treatment to currently available therapies in psoriatic arthritis patients who have been treated with at least one TNF inhibitor?

Much less likely to use

Less likely to use

Use comparably

More likely to use

Much more likely to use

___________

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

To read more Physician Views articles, click here.